Introduction {#s1}
============

Malaria is still a major global health threat with over 200 million new infections and around 400,000 deaths in 2017 ([@bib55]). Anemia is a common complication associated with malaria that contributes significantly to the great morbidity and mortality associated with the disease ([@bib54]). Despite its high clinical relevance, the mechanisms underlying malarial anemia in patients remain largely unknown. The difficulty in studying this syndrome arises at least in part from its multi-factorial etiology, as malaria causes both the clearance (through complement-mediated lysis or phagocytosis) of infected and uninfected erythrocytes and bone marrow dyserythropoiesis ([@bib16]; [@bib54]). The clearance of uninfected erythrocytes is thought to contribute significantly to anemia, because for each erythrocyte lysed directly due to *Plasmodium* infection, about eight uninfected erythrocytes are killed in *P. falciparum *infections ([@bib12]; [@bib35]) and about 34 erythrocytes are killed in *P. vivax* infections ([@bib3]).

The anti-parasite B-cell antibody response that is generated during the malaria blood stage represents an essential component of the protective immune response against this disease ([@bib5]; [@bib32]). However, an important autoimmune response is also generated during malaria, in which autoantibodies mediate some of the associated pathologies ([@bib11]; [@bib38]; [@bib36]). Specifically, autoantibodies that target membrane phosphatidylserine (PS) on uninfected erythrocytes promote anemia during malaria in mouse models, and these autoantibodies correlate with low hemoglobin levels in a cohort of *P.-falciparum-* and *P.-vivax-*infected patients with malarial anemia ([@bib2]; [@bib8]), establishing an autoimmune component to malarial anemia. An atypical group of B-cells that express the transcription factor T-bet secrete autoantibodies in different autoimmune mouse models ([@bib40]; [@bib41]) and were found to be major producers of anti-PS antibodies in mouse malaria ([@bib37]). The relation of these atypical T-bet^+^ B-cells to autoantibodies and their role in malarial anemia has not been assessed in malaria patients.

B-cells expressing the transcription factor T-bet have been identified in the circulation of individuals from malaria-endemic areas and implicated in the memory response against *Plasmodium *([@bib10]), being considered atypical memory B-cells ([@bib26]; [@bib52]). These cells are characterized as secreting low levels of antibodies and by inhibitory phenotypic markers such as FcRL5 ([@bib45]). The secreted-antibody specificity of these atypical memory B-cells has not been characterized because of their reduced effector function and minimal antibody secretion in-vitro ([@bib33]). Hence studying these FcRL5^+^T-bet^+^ B-cells during acute stage malaria in a population from a non-endemic area, such as European travelers, represents a unique opportunity to study the antibody specificity that results from recent primary activation.

In this study, we focused on measuring the levels of atypical FcRL5^+^T-bet^+^ B-cells in the circulation of *P.-falciparum*-infected returned travelers and its relation to autoantibodies and anemia development. Our results show that atypical FcRL5^+^T-bet^+^ B-cells are greatly expanded in acute malaria in *P.-falciparum*-infected patients and correlate with both anemia development and plasma anti-PS antibody levels in these patients. In vitro studies confirmed that the activation of FcRL5^+^T-bet^+^ B-cells by *P.-falciparum*-infected erythrocytes induces the secretion of anti-PS autoantibodies. All together, these findings attribute a role to atypical FcRL5^+^T-bet^+^ B-cells and anti-PS antibodies in the pathogenesis of human malarial anemia. Targeting these cells could have a therapeutic benefit in treating anemia during malaria.

Results {#s2}
=======

Specific autoantibodies correlate with malarial anemia and erythrocyte lysis capacity in *P.-falciparum*-infected patients {#s2-1}
--------------------------------------------------------------------------------------------------------------------------

In this study, we focused on samples (24 patients, 31 unique samples) from a cohort of *P.-falciparum*-infected returned travelers from Germany, who acquired malaria while visiting Africa. This cohort suffered from mild anemia with average hemoglobin levels of 12.4 g/dL (males) and 10.2 g/dL (females) (normal range is 13.8 to 17.2 and 12.1 to 15.1 g/dL, respectively) ([Table 1](#table1){ref-type="table"}).
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###### Clinical information from *P.-falciparum-*infected returned German travelers.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subject ID   Day of sampling^&^   Hemoglobin (g/dl)\*   Hemoglobin (g/dl)\*\*   Thrombocyte count (1000/µl)\*   Parasite count/µl\   Red blood cell (RBC) count (million/µl)\*\*   Sex   Age   Type of patient^\$^   Country of infection
                                                                                                                  \*\*, ^\#^                                                                                           
  ------------ -------------------- --------------------- ----------------------- ------------------------------- -------------------- --------------------------------------------- ----- ----- --------------------- ----------------------
  100          3                    10.3                  13.4                    135                             132,000              4.6                                           m     51    VFR                   Nigeria

  31           ND                   13.4                  ND                      132,000                         4.6                  m                                             51    VFR   Nigeria               

  101          8                    7.3                   12.1                    270                             1,860,000            3.89                                          f     56    T                     Gambia

  24           8.3                  12.1                  589                     1,860,000                       3.89                 f                                             56    T     Gambia                

  102          6                    13.5                  16.2                    140                             \<52,800             5.28                                          m     63    T                     Uganda

  27           ND                   16.2                  ND                      \<52,800                        5.28                 m                                             63    T     Uganda                

  103          2                    13.8                  14.4                    54                              46,900               4.69                                          m     38    VFR                   Guinea

  104          3                    12.6                  13.6                    130                             470,000              4.7                                           m     56    T                     Madagascar

  7            13.7                 13.6                  321                     470,000                         4.7                  m                                             56    T     Madagascar            

  105          5                    7.8                   8.1                     135                             1,050,000            3.5                                           f     53    VFR                   Kenya

  106          2                    10.8                  11.9                    9                               63,900               4.26                                          m     43    VFR                   Ghana

  107          3                    11.6                  12.4                    48                              \>430,000            4.3                                           m     52    VFR                   Ghana

  12           11.4                 12.4                  475                     \>430,000                       4.3                  m                                             52    VFR   Ghana                 

  108          0                    10.3                  10.3                    156                             176                  3.83                                          m     50    VFR                   Benin

  109          2                    10.5                  10.8                    98                              16                   3.73                                          m     62    VFR                   Ghana

  110          3                    12.3                  13.5                    128                             366,800              5.24                                          f     20    VFR                   Tanzania

  111          1                    13.5                  14.4                    23                              144,600              4.82                                          m     35    T                     Nigeria

  112          3                    13.1                  13.7                    70                              160,200              5.34                                          m     26    VFR                   Benin

  113          4                    10.7                  13.7                    74                              340,000              4.25                                          m     39    VFR                   Unknown

  114          3                    16.6                  18.7                    53                              4840                 5.96                                          m     26    T                     Ghana

  115          0                    12.6                  12.6                    53                              14,762               4.84                                          m     62    VFR                   Ghana

  116          2                    12.5                  12.9                    80                              26,917               4.58                                          f     43    VFR                   Cameroon

  4            10.4                 12.9                  106                     26,917                          4.58                 f                                             43    VFR   Cameroon              

  117          4                    15                    19.5                    32                              492,800              6.16                                          m     46    T                     Nigeria

  118          1                    11                    12.1                    20                              296,100              4.23                                          m     39    T                     Uganda

  119          1                    11.9                  11.9                    123                             29,800               4.02                                          f     25    VFR                   Ivory Coast

  3            11.6                 11.9                  116                     29,800                          4.02                 f                                             25    VFR   Ivory Coast           

  120          0                    16.1                  16.1                    102                             7896                 5.36                                          m     38    VFR                   Guinea Bissau

  121          2                    14.4                  15.7                    119                             496                  5.48                                          m     34    VFR                   Nigeria

  122          2                    ND                    13.5                    ND                              74                   5.15                                          m     18    VFR                   Togo

  123          2                    12.8                  14.2                    60                              49,800               4.98                                          m     52    VFR                   Ghana
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^&^Days since treatment start to sampling, \*Measurement at day of sampling, \*\*Measurement at day of presentation, ^\#^Parasitemia expressed in infected erythrocytes per µl of blood, ^\$^Tourist (T), Visiting Friend or Relative (VFR). ND, not determined.

As described before in other cohorts with mild anemia ([@bib7]; [@bib47]), hemoglobin levels in this cohort do not significantly correlate with parasitemia ([Figure 1A](#fig1){ref-type="fig"}), confirming that direct erythrocyte infection by *Plasmodium* is not a major cause of anemia and indicating that other mechanisms must contribute to this pathology. This is in agreement with previous findings reporting major losses of uninfected erythrocytes and dyserythropoiesis during malaria ([@bib54]).

![Specific autoantibodies correlate with malarial anemia in *P.-falciparum-*infected returned travelers.\
Non-parametric Spearman correlation analysis comparing hemoglobin with (**A**) parasitemia, (**B**) anti-PS IgG antibodies, (**C**) anti-PfEBA IgG antibodies, (**D**) anti-erythrocyte IgG antibodies and (**E**) anti-DNA IgG antibodies.\
10.7554/eLife.48309.004Figure 1---source data 1.Source data for [Figure 1](#fig1){ref-type="fig"} .](elife-48309-fig1){#fig1}

As we had previously observed that autoimmune anti-PS antibodies induce anemia during malaria in a mouse model ([@bib8]; [@bib37]), we determined whether hemoglobin levels correlated with autoimmune anti-PS IgG antibodies in our cohort. We observed an inverse correlation between anti-PS antibodies and hemoglobin levels ([Figure 1B](#fig1){ref-type="fig"}), which was not found for IgG antibodies against the *P. falciparum* erythrocyte binding antigen (PfEBA) ([Figure 1C](#fig1){ref-type="fig"}), suggesting that an autoimmune response contributes to the development of anemia in malaria.

To further dissect the role that autoantibodies could be playing during malarial anemia in *P.-falciparum*-infected patients, we analyzed other relevant autoantibodies: anti-erythrocyte and anti-DNA IgG antibodies. As expected, our results show that plasma anti-erythrocyte IgG antibodies also correlate with the development of malarial anemia, showing a significant negative correlation with hemoglobin from the samples of *P.-falciparum*-infected returned travelers ([Figure 1D](#fig1){ref-type="fig"}). These antibodies recognized all kinds of antigens in human erythrocyte lysates ([@bib21]; [@bib20]), including PS. The similarities in the correlations between anti-PS and anti-erythrocyte IgG antibodies and anemia may indicate that anti-PS antibodies are the major antibody specificity driving anemia.

In addition, our results show that anti-DNA IgG antibodies, which are typical in autoimmune diseases ([@bib49]), do not correlate with anemia ([Figure 1E](#fig1){ref-type="fig"}), suggesting that the specificity of the autoimmune antibody response is important for the development of anemia. Collectively, these initial correlations point to an autoimmune origin of malarial anemia, and confirm that the cohort of *P.-falciparum-*infected returned travelers is an adequate study group for testing the contribution of atypical B-cells in malarial anemia.

As malarial anemia is characterized by the lysis of uninfected erythrocytes and by an increase in lactate dehydrogenase (LDH) in the plasma ([@bib6]), we determined whether anti-PS IgG antibodies correlate with the levels of LDH in the patient's plasma ([Figure 2A](#fig2){ref-type="fig"}). We observed a significant positive correlation, which suggests that autoimmune anti-PS IgG antibodies may induce the lysis of erythrocytes during malaria. We next determined whether erythrocyte lysis capacity was increased in the plasma of *P.-falciparum*-infected patients. Using an in vitro complement lysis assay of human erythrocytes exposing PS, we observed that plasma from patients was significantly more effective than healthy control plasma in lysing human erythrocytes ([Figure 2B](#fig2){ref-type="fig"}).

![Plasma from *P. falciparum* patients mediates erythrocyte lysis, which can be partially inhibited by Annexin V.\
(**A,B**) Correlation of plasma anti-PS IgG antibodies with the LDH levels (**A**) or with the erythrocyte lysis capacity (**B**) of the plasma of *P. falciparum* patients. (**C**) Complement-mediated lysis of erythrocytes exposing PS by *P. falciparum* patient's plasma compared to plasma from uninfected controls, expressed as percentage of maximal lysis. (**D**) Complement-mediated lysis of erythrocytes exposing PS, pre-incubated or not with Annexin V, before incubation with the plasma of *P. falciparum* patients (n = 6). Results show the means and standard deviations of triplicated determinations. Significance was assessed by nonparametric Spearman correlation analysis (**A,B**) or unpaired Student\'s t-test (**C,D**). \*p≤0.05, \*\*p≤0.01.\
10.7554/eLife.48309.006Figure 2---source data 1.Source data for [Figure 2](#fig2){ref-type="fig"}.](elife-48309-fig2){#fig2}

We then studied the relation of anti-PS IgG levels and the erythrocyte lysis capacity in the patient's plasma, as determined using the in vitro complement lysis assay. We observed a direct correlation between anti-PS and erythrocyte lysis capacity ([Figure 2C](#fig2){ref-type="fig"}), which suggests that anti-PS IgG antibodies may contribute to anemia in malaria by inducing the complement-mediated lysis of uninfected erythrocytes.

To determine the anti-PS specificity of the erythrocyte lysis, we pre-incubated the erythrocytes with annexin V, a protein that specifically binds to PS and inhibits the binding of anti-PS antibodies ([@bib8]; [@bib50]), finding a partial reduction of the erythrocyte lysis capacity in the plasma samples ([Figure 2D](#fig2){ref-type="fig"}). It is likely that other antibody specificities ([@bib21]; [@bib20]) in addition to anti-PS also contribute to erythrocyte lysis in malaria patients. Taken together, these results suggest that anti-PS antibodies mediate the lysis of uninfected erythrocytes that expose PS during malaria.

Atypical memory FcRL5^+^T-bet^+^ B-cells are greatly expanded in *P.-falciparum*-infected patients {#s2-2}
--------------------------------------------------------------------------------------------------

Because our previous studies in mice and previous reports in human malaria patients had shown a large increase in atypical memory B-cell (MBC) population upon infection with *Plasmodium* ([@bib28]; [@bib29]; [@bib33]; [@bib37]; [@bib46]; [@bib52]), we next analyzed the total levels of atypical MBCs in peripheral blood mononuclear cells (PBMC) in the cohort of *P.-falciparum*-infected returned travelers. We characterized atypical MBCs by the double expression of FcRL5 and T-bet, as both markers are highly expressed and characteristic of this population ([Figure 3A](#fig3){ref-type="fig"}). This population is known to be elevated in malaria patients from endemic areas ([@bib26]; [@bib46]). After gating out non-B-cells (CD19^--^), we observed that FcRL5^+^T-bet^+^ B-cells are indeed expanded in the PBMC samples from *P.-falciparum*-infected German returned travelers when compared to samples from uninfected German controls ([Figure 3B](#fig3){ref-type="fig"}).

![Atypical MBCs expand in *P.-falciparum-*infected patients and decline after treatment.\
(**A**) Gating strategy for the characterization of FcRL5^+^ T-bet^+^ B-cells (CD19^+^) with representative plots of one uninfected control and one *P. falciparum* patient. (**B**) Percentage of CD19^+^ FcRL5^+^ T-bet^+^ B-cells in samples from uninfected controls and *P. falciparum* patients. Significance assessed by unpaired Student\'s t test. \*\*\*\*p≤0.0001.\
10.7554/eLife.48309.014Figure 3---source data 1.Source data for [Figure 3](#fig3){ref-type="fig"}.](elife-48309-fig3){#fig3}

We further analyzed the cohort of *P.-falciparum*-infected returned travelers by considering two different groups: 1) tourists, who reported to be naïve to malaria, and 2) those visiting friends or relatives (VFR), who reported having at least one previous episode of malaria ([Table 1](#table1){ref-type="table"}). We did not observe any significant difference in the levels of atypical MBCs in the PBMC between these two groups ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). We also observed no significant gender difference between the levels of FcRL5^+^T-bet^+^ B-cells in PBMC ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Furthermore, we found no significant correlation between the time after treatment at which samples were obtained (ranging from 0 to 31 days, [Table 1](#table1){ref-type="table"}) and the level of hemoglobin, which indicates that the variations in hemoglobin levels are not just a consequence of time after parasite clearance. We also observed a significant direct correlation between the levels of atypical MBCs and the days after treatment, which suggests that the levels of these cells continue to increase after treatment. This increase is compatible with the activation of atypical MBCs during infection and their continuing proliferation after parasite clearance ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}).

Altogether, these initial results suggest an expansion of atypical FcRL5^+^T-bet^+^ B-cells in *P.-falciparum*-infected patients following acute infection.

Atypical memory FcRL5^+^T-bet^+^ B-cells correlate with hemoglobin levels in *P.-falciparum*-infected returned travelers {#s2-3}
------------------------------------------------------------------------------------------------------------------------

We next sought to determine whether atypical MBCs correlate with hemoglobin levels in *P. falciparum* patients. For this purpose, we performed a B-cell sub-population gating analysis in PBMC samples from our cohort. Following classical gating strategies for all relevant B-cell (CD19^+^) sub-populations from human PBMC ([@bib52]), we analyzed: (i) naïve B-cells (CD27^--^CD21^+^CD10^--^), (ii) immature B-cells (CD10^+^), (iii) plasma cells (CD27^+^CD21^--^CD20^--^), (iv) classical MBCs (CD27^+^CD21^+^) and (v) atypical MBCs (FcRL5^+^T-bet^+^) ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). To define the atypical and classical MBC populations better, we analyzed the expression of T-bet in FcRL5^+^ cells compared to classical MBCs, finding that the expression of T-bet is significantly higher in FcRL5^+^ cells ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

We found a significant inverse correlation between hemoglobin levels and atypical MBCs levels in the PBMC samples from *P. falciparum* patients ([Figure 4A](#fig4){ref-type="fig"}). Atypical MBCs did not significantly correlate with other relevant parameters such as parasitemia ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}), but did correlate positively with the age of the patient ([Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}), supporting previous studies that initially denominated these cells as Age-associated B-cells ([@bib31]). We also analyzed a possible relation of atypical MBCs with thrombocytopenia, another complication that frequently accompanies malaria and has an autoimmune component to its pathology ([@bib15]). We did not observe any significant correlation between the levels of atypical MBCs and thrombocyte counts in our cohort of patients ([Figure 4---figure supplement 5](#fig4s5){ref-type="fig"}), suggesting that atypical MBCs specifically correlate with anemia and not with other malaria-associated complications.

![The atypical MBC subset correlates with the development of anemia in *P. falciparum* patients.\
Correlation analysis of atypical (**A**) and classical (**B**) MBC subsets from the PBMC of *P. falciparum* patients compared with hemoglobin levels. Significance was assessed by non-parametric Spearman correlation analysis.\
10.7554/eLife.48309.027Figure 4---source data 1.Source data for [Figure 4](#fig4){ref-type="fig"}.](elife-48309-fig4){#fig4}

Interestingly, we observed that classical memory B-cells (CD27^+^CD21^+^) had a significant positive correlation with hemoglobin levels ([Figure 4B](#fig4){ref-type="fig"}). We did not find any significant correlation between hemoglobin level and percentage of naïve B-cells or immature B-cells, but observed a significant positive correlation with percentage of plasma cells ([Figure 4---figure supplement 6](#fig4s6){ref-type="fig"}).

Taken together, these results suggest that atypical MBCs, but not other B-cell subtypes, are specifically implicated in malaria-induced anemia in patients.

Atypical memory B-cells correlate with anti-PS IgG antibodies in *P.-falciparum*-infected patients {#s2-4}
--------------------------------------------------------------------------------------------------

During *Plasmodium* infections in mice, T-bet^+^ B-cells secrete anti-PS IgG antibodies that induce premature clearance of uninfected erythrocytes, promoting malarial anemia ([@bib8]; [@bib37]). The role of anti-PS IgG antibodies and the B-cells that secrete them during malarial anemia in *P.-falciparum*-infected patients has not been studied before. In this cohort of *P.-falciparum*-infected German returned travelers, we observed an inverse correlation between anti-PS IgG antibodies and hemoglobin, suggesting a role of these autoantibodies in promoting anemia in this cohort ([Figure 1B](#fig1){ref-type="fig"}). As both FcRL5^+^T-bet^+^ atypical B-cells and anti-PS IgG antibodies correlate with hemoglobin levels in our cohort, we assessed the relationship between the levels of FcRL5^+^T-bet^+^ atypical B-cells and anti-PS IgG antibodies. Our results show a significant positive correlation between FcRL5^+^T-bet^+^ atypical MBCs and anti-PS IgG antibodies ([Figure 5A](#fig5){ref-type="fig"}), possibly implicating these cells as the major producers of the antibodies. In accordance with the hemoglobin results ([Figure 4B](#fig4){ref-type="fig"}), we also found a significant inverse relationship between anti-PS IgG antibodies and classical MBCs (CD27^+^CD21^+^) ([Figure 5B](#fig5){ref-type="fig"}). As shown before for hemoglobin ([Figure 4---figure supplement 6](#fig4s6){ref-type="fig"}), neither naïve nor immature B-cells presented a significant correlation with the levels of plasma anti-PS IgG antibodies ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Plasma cells, which previously correlated with hemoglobin levels, did not correlate with anti-PS IgG antibodies, suggesting that their role in anemia may be mediated through the secretion of antibodies that have different specificities. These results establish a relationship between atypical MBCs and anti-PS IgG antibodies.

![Anti-PS IgG antibodies show distinct correlations with classical and atypical MBC subsets in *P. falciparum* patients.\
Correlation analysis of levels of (**A**) atypical and classical (**B**) MBCs with anti-PS IgG antibody levels from the plasma of *P. falciparum* patients. (**C**) Correlation analysis of atypical and classical MBC levels. Significance was assessed by non-parametric Spearman correlation analysis.\
10.7554/eLife.48309.035Figure 5---source data 1.Source data for [Figure 5](#fig5){ref-type="fig"}.](elife-48309-fig5){#fig5}

As an inverse relationship between classical and FcRL5^+^T-bet^+^ atypical MBCs was found with hemoglobin and anti-PS antibodies, we analyzed whether there was any correlation between the levels of these two populations. Accordingly, we found a significant negative correlation between the levels of classical and FcRL5^+^T-bet^+^ atypical MBCs ([Figure 5C](#fig5){ref-type="fig"}). These results suggest a possible relationship between classical and atypical MBC populations, but may also be interpreted as the result of a robust proliferation of atypical MBCs, which would decrease the proportion of classical MBCs among the CD19^+^ population even if their actual numbers had not decreased.

In addition, we assessed the levels of two other autoantibodies (anti-erythrocyte and anti-DNA) to further characterize the autoantibody repertoire that correlates with malaria anemia in *P.-falciparum*-infected patients. We first analyzed the relationship between anti-erythrocyte IgG antibodies and all of the B-cell sub populations. The analysis of memory B-cell subsets and anti-erythrocyte IgG antibodies resembles the anti-PS IgG antibodies correlations, showing a positive significant correlation between FcRL5^+^T-bet^+^ atypical MBCs. No significant correlation was found with classical memory, naïve or immature B-cell subsets. A positive correlation was observed with plasma cells, suggesting that other autoantibodies besides anti-PS are produced by these cells, possibly explaining the previous correlation of plasma cells with hemoglobin levels ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).

We also analyzed possible correlations of the levels of plasma anti-DNA antibodies with all of the B-cell subpopulations ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). We did not observe any significant correlation with atypical MBCs, suggesting that anti-DNA antibodies are not predominantly produced by this subpopulation of B-cells. The lack of correlation with other B-cell sub-populations (naïve, immature, plasma cell, and classical memory) does not provide any indications on the B-cell subtype that produces these antibodies. Anti-DNA antibodies do not correlate with hemoglobin levels in our cohort ([Figure 1E](#fig1){ref-type="fig"}), so it is likely that they do not play a role in this pathology and therefore are not expected to correlate with relevant B-cells subsets that contribute to anemia.

Atypical memory B-cells do not correlate with anti-PfEBA antibodies in *P.-falciparum*-infected patients {#s2-5}
--------------------------------------------------------------------------------------------------------

We also assessed the relationship between plasma anti-parasite antibodies (anti-PfEBA) and the different B-cell subsets in our cohort of *P.-falciparum*-infected patients. As specific plasma autoantibodies (anti-PS and anti-erythrocyte, but not anti-DNA) correlate distinctly with the atypical MBC subset and with anemia development, we questioned whether there is any correlation between any of the different B-cell subsets and anti-parasite antibodies (anti-PfEBA). This analysis showed no significant correlation between anti-PfEBA IgG antibodies and any of the B-cells subsets assessed ([Figure 6](#fig6){ref-type="fig"}). Anti-PfEBA IgG antibodies presented no significant correlation with anemia in patients ([Figure 1C](#fig1){ref-type="fig"}), so the lack of correlation with FcRL5^+^T-bet^+^ atypical MBCs, which tightly correlate with anemia, is expected and further supports the lack of involvement of anti-parasite antibodies in malarial anemia.

![There is no significant correlation of anti-parasite *PfEBA* antibodies with relevant B-cell subsets from *P. falciparum patients*.\
Correlation analysis of (**A**) atypical MBCs, (**B**) classical MBCs, (**C**) plasma cells, (**D**) naïve B-cells, and (**E**) immature B-cells with anti-*P. falciparum* (PfEBA) IgG antibody levels from the plasma of *P. falciparum* patients. Significance was assessed by non-parametric Spearman correlation analysis.\
10.7554/eLife.48309.037Figure 6---source data 1.Source data for [Figure 6](#fig6){ref-type="fig"}.](elife-48309-fig6){#fig6}

FcRL5^+^T-bet^+^ atypical B-cells secrete anti-PS antibodies upon stimulation with *P.-falciparum-*infected erythrocytes in vitro {#s2-6}
---------------------------------------------------------------------------------------------------------------------------------

We have observed a strong significant correlation between FcRL5^+^T-bet^+^ B-cells, anti-PS antibodies and malarial anemia in a cohort of *P.-falciparum*-infected patients ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). As these data from patient samples are limited to the analysis of correlations between different parameters, we aimed to determine directly whether activation of FcRL5^+^T-bet^+^ atypical B-cells can induce the secretion of anti-PS antibodies. Expansion of T-bet^+^ B-cells and secretion of anti-PS antibodies into the culture medium was observed in vitro after incubation of PBMC from healthy donors with lysates of *P.-falciparum-*infected erythrocytes ([@bib37]). To determine whether the T-bet^+^ B-cells that are activated in these experiments are also FcRL5^+^ and, more importantly, whether they specifically secrete anti-PS antibodies, we incubated PBMC from healthy US individuals with *P.-falciparum-*infected erythrocyte lysates. We observed a robust expansion of FcRL5^+^T-bet^+^ B-cells compared to cells incubated with uninfected erythrocyte lysate or with no stimulation ([Figure 7A](#fig7){ref-type="fig"}). To investigate specifically whether these in vitro *P.-falciparum*-induced FcRL5^+^ T-bet^+^ atypical B-cells secrete anti-PS antibodies, we first enriched this population by selecting FcRL5^+^ cells from PBMC stimulated with *P.-falciparum-*infected erythrocyte lysate. Remarkably, ELISPOT analysis of the antibody specificity of enriched FcRL5^+^ cells showed significantly increased numbers of anti-PS-specific B-cells in the FcRL5^+^ population when compared to enriched CD27^+^ cells, which would represent predominantly classical memory B-cells and plasmablast/plasma cells ([Figure 7B](#fig7){ref-type="fig"}). No significant difference is observed between the number of FcRL5^+^antibody-secreting cells (ASCs) producing anti-PS and the number of anti-PfEBA cells, suggesting that the FcLR5^+^ subset can efficiently produce both autoimmune and anti-parasite antibodies.

![*P. falciparum* drives the expansion of human FcRL5^+^ T-bet^+^ B-cells that secrete anti-PS antibodies in vitro.\
(**A**) Percentage of T-bet^+^FcRL5^+^ B-cells that expanded from the PBMCs of a healthy naïve donor after in-vitro exposure to either uninfected erythrocyte lysate (uLysate) or *P. -falciparum*-infected erythrocyte lysate (iLysate). (**B**) ELISPOT of enriched populations for either FcRL5 (gray bars) or CD27 (black bars) from PBMCs of healthy naïve US donors after in-vitro exposure to *P.-falciparum*-infected erythrocyte lysate (iLysate) (N = 3). ASC, antibody-secreting cells. Significance assessed by unpaired Student\'s t test. \*\*p≤0.01, \*\*\*p≤0.001.\
10.7554/eLife.48309.041Figure 7---source data 1.Source data for [Figure 7](#fig7){ref-type="fig"}.](elife-48309-fig7){#fig7}

As FcRL5 is upregulated transiently on activated B-cells ([@bib4]), the population expressing this molecule could include not only atypical B-cells but also any recently activated B-cell. However, we observed that CD27^+-^enriched cells had higher numbers of total ASCs than FcLR5^+^ ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}), which indicates that activated ASCs are found in both populations (CD27^+^ and FcLR5^+^) and that the FcLR5^+^ population does not include most of the activated B cells. Distinctly, quantification of PS-specific ASCs shows that these cells are more frequent among FcLR5^+^ cells than amongCD27^+^ cells, despite having similar numbers of PfEBA-specific and total ASCs. These results indicate that both enriched populations have similar numbers of activated B-cells, but FcLR5^+^ cells contain more anti-PS-secreting cells than CD27^+^ cells.

Stimulation of PBMC with a specific *P. falciparum* antigen, Histidine Rich Protein II (HRPII), or with uninfected erythrocyte lysate did not induce a significant expansion of FcRL5^+^T-bet^+^ cells in these cultures ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). This may be explained by the observation that the three different signals that are needed for optimal expansion of these cells in vitro---B-cell receptor stimulation, specific inflammatory cytokines (IFNγ/ ΙL−21) and *Plasmodium* DNA ([@bib31]; [@bib37])---are present in the co-cultures of PBMC with infected lysates, but not in co-cultures with uninfected lysates or purified proteins that lack *Plasmodium* DNA.

Taken together, these results indicate that atypical FcRL5^+^T-bet^+^ B-cells produce anti-PS antibodies upon stimulation with parasite lysates in vitro and probably contribute to malarial anemia in patients through the secretion of anti-PS antibodies.

Discussion {#s3}
==========

Malarial anemia in *P.-falciparum-*infected patients has been a complex subject of study because of its multi-factorial etiologies and the complicated logistics of endemic sites ([@bib16]; [@bib30]; [@bib35]). Although several studies in vitro and in mouse models have analyzed possible mechanisms mediating anemia in malaria ([@bib21]; [@bib20]; [@bib37]; [@bib42]), very few studies have been able to translate their findings to malaria patients ([@bib27]; [@bib16]; [@bib24]). Autoimmunity has been proposed to mediate malaria-associated anemia through the induced-clearance of uninfected erythrocytes bound to anti-PS antibodies ([@bib8]). Studies in mice identified T-bet^+^ B-cells as the immune cell type secreting these anti-PS antibodies ([@bib37]). In this study, we focused on *P. falciparum* patients to test whether malaria-associated anemia correlates with the autoimmune anti-PS response and with FcRL5^+^T-bet^+^ B-cells, which would be consistent with a causal relationship.

The observed correlation of hemoglobin levels with anti-PS and anti-erythrocyte IgG levels, but not with anti-DNA IgG antibodies, confirms the specificity of the autoimmune response that contributes to malarial anemia in patients. However, this specificity may not be limited to PS, as the erythrocyte lysis capacity of the patient's plasma was only partially inhibited when anti-PS binding was blocked, suggesting that other antibody specificities may contribute to the lysis of erythrocytes ([@bib21]; [@bib20]). We also observed that anti-erythrocyte antibody levels correlate with hemoglobin levels, plasma cells and atypical MBCs frequency, and both B-cell subsets also correlate with hemoglobin levels. Taken together, these results suggest that other autoimmune antibodies in addition to anti-PS, possibly secreted by plasma cells and atypical MBCs, may contribute to anemia in malaria patients.

The direct correlation of anti-PS antibodies with levels of LDH \[which are increased as a result of erythrocyte lysis during malarial anemia ([@bib44]; [@bib54])\] and with the erythrocyte lysis capacity of the plasma supports the hypothesis that autoimmune anti-PS antibodies contribute to anemia in malaria through complement-mediated lysis. Previous results showed increased macrophage phagocytosis of uninfected erythrocytes from I-infected mice that was mediated by anti-PS antibodies ([@bib8]). It is likely that both complement-mediated lysis and phagocytosis may be mediated by anti-PS antibodies, contributing to malaria-induced anemia.

T-bet^+^ B-cells have been widely studied in the context of autoimmunity ([@bib23]; [@bib40]; [@bib39]), in particular in relation to systemic lupus erythematosus (SLE) ([@bib31]). In this context, these cells have been suggested as major candidates for drivers of the pathological anti-nuclear antibody response that mediates the SLE-associated pathologies ([@bib41]; [@bib51]). In the context of malaria, T-bet was found to be a key marker of atypical MBCs that are expanded in individuals living in malaria endemic areas ([@bib26]; [@bib34]). Here, we have also used FcRL5, in addition to T-bet, as a marker to define better atypical MBCs in *P. falciparum* patients ([@bib45]), as T-bet alone can identify a rather heterogenic population ([@bib9]). Atypical MBCs have been characterized mainly after repeated seasonal infections ([@bib1]; [@bib25]; [@bib28]; [@bib43]; [@bib45]; [@bib52]; [@bib53]), which is in agreement with our findings of increased levels of atypical MBCs in primary infections.

Some studies characterized ex-vivo atypical MBCs that had markedly reduced effector function and low antibody secretion capacity ([@bib26]; [@bib34]; [@bib33]). Although the unresponsiveness of these cells to direct ex-vivo stimulation with different standard stimuli suggested that these cells were inactive ([@bib26]), both atypical and classical MBCs from malaria patients are capable of secreting antibodies against blood-stage *P. falciparum* antigens ([@bib14]; [@bib18]; [@bib22]; [@bib34]) ([@bib13]; [@bib29]; [@bib48]). This is in agreement with our results from PBMC stimulated in vitro, in which FcRL5-enriched cells show reactivity against both PS and the PfEBA antigen.

Atypical MBCs have also been described in *Plasmodium*-infected mice, where they were characterized as short-lived, and therefore not contributing to the long-lived anti malaria immune response ([@bib29]), but where they were able to limit the protective anti-parasite antibody response ([@bib10]). In our previous study in mice, we characterized T-bet^+^ B-cells as the main producers of anti-PS IgG antibodies during malarial anemia ([@bib37]).

Although several studies have described atypical MBCs in individuals living in malaria endemic areas ([@bib13]; [@bib22]; [@bib26]; [@bib33]; [@bib45]; [@bib48]; [@bib52]), few studies had previously focused on these cells during the acute infection of individuals from non-endemic areas, where primary infections can be observed. It is likely that atypical MBCs have frequently been characterized as exhausted memory B-cells secreting minimal antibodies because the studies were performed in individuals from endemic areas who had previously suffered numerous malaria infections. Our cohort offers a differential advantage in enabling the study of atypical MBCs during primary *Plasmodium* infections (in the group of tourists), allowing the characterization of these cells during their first response to malaria in a unique setting and thus dissecting their contribution in patients without other endemic site bystander infections. We also observed that the VFR group, whose members reported previous malaria infections, presents levels of atypical MBCs that are similar to those seen in first-infection patients. Although the time after their last malaria infection is variable in this group, these patients are very different from individuals suffering continuous reinfections in endemic areas.

The correlation of expansion of atypical MBCs with anemia in patients suggests that these cells have a role in malaria pathogenesis, providing clinical significance to our findings. In addition, the lack of correlation between the prevalence of these cells and other clinical parameters, such as parasitemia, gender, patient background and thrombocyte count, points to the specificity of the pathological effect.

In mice, T-bet^+^ B-cells are major producers of anti-PS antibodies during malaria and promote anemia by inducing the clearance of uninfected erythrocytes that bind to these antibodies ([@bib8]; [@bib37]). T-bet^+^ B-cells in these mice are activated directly by *Plasmodium* DNA through TLR-9 alongside IFN-γ to produce anti-PS antibodies ([@bib37]). Our observations suggest that a similar mechanism contributes to human malarial anemia, as we observed specific direct correlations between the three key elements of this process: anti-PS antibodies, atypical MBCs and anemia. Our results in human samples also provide evidence that FcRL5^+^T-bet^+^ B-cells correlate with anemia. These cells are observed circulating in high levels in individuals living in malaria-endemic areas and present low antibody secretion ex vivo ([@bib33]). It is likely that at least some of these atypical MBCs may be derived from the T-bet^+^FcRL5^+^ B-cells observed in our study, which are generated during primary acute malaria but would lose their antibody-secreting capacity over time.

To complement the studies with patient samples, we took a direct approach to determine whether atypical MBCs can secrete anti-PS antibodies upon activation. The detection of anti-PS-secreting FcRL5^+^ B-cells, but not of anti-PS-secreting CD27^+^ B-cells, after stimulation with *P.-falciparum*-infected erythrocyte lysates, directly links FcRL5^+^ B-cells with autoimmune antibody secretion in response to parasite stimulation.

Collectively, results from the analysis of patient samples and from in vitro stimulation of healthy PBMC, suggest that atypical T-bet^+^FcRL5^+^ memory B-cells contribute to malarial anemia in *P.-falciparum*-infected patients through anti-PS antibody secretion. They also strengthen the dichotomy within memory B-cells, where the atypical subset correlates with autoimmune anemia while the classical subset correlates with hematological health. As there were no significant correlations between anti-PS IgG antibodies and the other B-cell subsets (naïve, immature, classical memory or plasma cells), or of other antibodies (DNA, PfEBA) with anemia or with atypical memory B-cells, these results suggest specificity and support the hypothesis that atypical T-bet^+^FcRL5^+^ memory B-cells secrete anti-PS IgG antibodies that contribute to malarial anemia in *P.-falciparum*-infected patients.

In summary, our results provide the first mechanistic evidence of autoimmune-mediated malaria anemia in patients, and suggest that atypical T-bet^+^FcRL5^+^ B-cells are major promoters of this pathology in *P.-falciparum*-infections. Given the need for novel targeted treatments for malarial anemia, which still presents high prevalence and mortality, the unique phenotype and specificity of these cells secreting anti-PS antibodies could enable biomarker identification and the development of targeted therapeutics.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                        Designation                                    Source or\              Identifiers      Additional information
  (species) or\                                                                       reference                                
  resource                                                                                                                     
  ------------------------------------ ---------------------------------------------- ----------------------- ---------------- ------------------------
  Biological sample (*Homo sapiens*)   CPD backed cells                               Interstate Blood bank                    

  Antibody                             Anti-human CD20 (mouse monoclonal)             Biolegend               302304           1:100

  Antibody                             Anti- T-bet (mouse monoclonal)                 Biolegend               644810           1:100

  Antibody                             Anti-human CD11c (mouse monoclonal)            Biolegend               301604           1:100

  Antibody                             Anti-human CD27 (mouse monoclonal)             Biolegend               302806           1:100

  Antibody                             Anti-human CD21 (mouse monoclonal)             Biolegend               354910 (FITC)\   1:100
                                                                                                              354906 (APC)     

  Antibody                             Anti-human FcRL5 (mouse monoclonal)            Biolegend               340306           1:100

  Antibody                             Anti-human CD10 (mouse monoclonal)             Biolegend               312210           1:100

  Antibody                             Anti-human CD19 (mouse monoclonal)             Biolegend               30228            1:100

  Antibody                             Anti-human IgM- HRP (goat polyclonal)          Millipore               AP114P           1:2000

  Antibody                             Anti-human IgG-HRP (goat polyclonal)           GE Healthcare           NA933            1:2000

  Antibody                             Anti-human FcRL5-biotin (mouse monoclonal)     Miltenyi Biotec         130-105-993      1:100

  Antibody                             Anti-human IgM unlabeled (mouse monoclonal)    Biolegend               314--502         15 μg/ml

  Antibody                             Anti-human IgM-biotin(mouse monoclonal)        EMD Millipore           411543           1 μg/ml

  Peptide, recombinant protein         *P. falciparum* Erythrocyte Binding Antigen    BEI Resources\          \#MRA-1162       15 μg/ml
                                                                                      MR-4                                     

  Commercial assay or kit              True-Nuclear Transcription Factor Buffer Set   Biolegend               424401           

  Commercial assay or kit              MycoAlert Mycoplasma Detection Kit             Lonza                   LT07-118         

  Commercial assay or kit              TMB substrate                                  BD Biosciences          555214           

  Commercial assay or kit              CD27 Microbeads human                          Miltenyi Biotec         130-051-601      

  Chemical compound, drug              Ionomycin                                      Life technologies       I24222           2.5 µM

  Chemical compound, drug              Ficoll-Paquee Plus                             GE Life Sciences        17144002         

  Software, algorithm                  GraphPad PRISM                                 GraphPad PRISM                           

  Other                                Phosphatidylserine                             Sigma-Aldrich           P7769            20 μg/ml

  Other                                Calf Thymus DNA                                Sigma-Aldrich           D4522            10 μg/ml

  Other                                Stop buffer                                    Biolegend               423001           

  Other                                Annexin V                                      Biolegend               640902           0.5 µM

  Other                                X- VIVO 15 media                               Lonza                   04-418Q          

  Other                                Human AB healthy plasma                        Sigma-Aldrich           H4522            
  -----------------------------------------------------------------------------------------------------------------------------------------------------

Study design and sample collection {#s4-1}
----------------------------------

Patients were recruited at the University Medical Center Hamburg-Eppendorf. Inclusion criteria were age between 18 and 65 years, hemoglobin \>8 g/dl and a diagnosis of *P. falciparum* malaria by microscopy. All individuals gave written informed consent. The study protocol was approved by the ethics committee of the Hamburg Medical Association (PV4539). Plasma and PBMC were isolated from peripheral venous blood by Ficoll purification and stored at −80°C until temperature-controlled transportation to New York University. The sample size was limited by the number of German patients reporting with *P. falciparum* infection at University Medical Center Hamburg-Eppendorf during one year. We obtained samples from 24 patients (at two different times after infection for seven of them) and four uninfected controls ([Table 1](#table1){ref-type="table"}). Spearman analysis of the seven pairs of repeated samples showed no significant correlation in the levels of atypical MBCs between repeated measurements. All patients received anti-malaria treatment on the day of presentation, which is considered day 0. Patients were classified as tourists or VRF. The latter is not a homogeneous group as it encompasses people who were born in their (non-malaria endemic) country of residence as well as people who had arrived in the current country of residence at any time before their current infection.

*P. falciparum* culture and isolation {#s4-2}
-------------------------------------

Erythrocyte asexual stage cultures of the *P. falciparum* strain 3D7 were maintained at 5% hematocrit in RPMI 1640, 25 mM HEPES supplemented with 10 μg/ml gentamycin, 250 μM hypoxanthine, 25 mM sodium bicarbonate, and 0.5% Albumax II (pH 6.75) under atmospheric conditions of 5% oxygen, 5% carbon dioxide, and 90% nitrogen. Magnetic separation of late stages with MACS cell separation columns (Miltenyi Biotec) was used for culture synchronization and to isolate late-stage-infected erythrocytes for use in experiments. For experiments with lysates, late-stage infected erythrocytes were lysed by 10 freeze/thaw cycles. *P. falciparum* culture supernatants were tested for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza LT07-118) and found to be negative.

Human PBMC enrichment {#s4-3}
---------------------

Peripheral venous blood from healthy malaria-naïve donors was obtained on the day of the experiment at the New York University Clinical and Translational Science Institute with sodium citrate as anticoagulant. Institutional Review Board (IRB) approval was obtained at New York University School of Medicine. PBMC were enriched using Ficoll-Paque PLUS (GE Life Sciences). All recruited volunteers provided written informed consent prior to blood donation.

Flow cytometry {#s4-4}
--------------

All flow cytometry was performed on a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ) and analyzed with FlowJo (Tree Star, Ashland, OR). All Abs for FACS were purchased from BioLegend (San Diego, CA). For PBMC assays, PBMC were stained with anti-human: FITC anti-CD20 (2H7), PE anti-T-bet (4B10), FITC anti-CD11c (3.9), FITC anti-CD27 (O323), FITC anti-CD21 (Bu32), APC anti-CD21 (Bu32), APC anti-FcRL5 (509f6), APC anti-CD10 (HI10a), and PRCP anti-CD19 (HIB19). Intracellular T-bet staining was performed using the True-Nuclear Transcription Factor Buffer Set (Biolegend) and following manufacturer's instructions. Two to three technical replicates (independent labeling of PBMC and FACs analysis) for B-cell subpopulations were performed when the number of PBMC collected from each patient allowed for it (15 samples). The average value of technical replicates for each sample was used for statistical analysis.

ELISA {#s4-5}
-----

Costar 3590 ELISA plates were coated with PS at 20 μg/ml or human uninfected erythrocytes lysate (10^9^ erythrocytes/ml in PBS) diluted 1:500 in 200 proof molecular biology ethanol or with *P. falciparum* Erythrocyte Binding Antigen (PfEBA, which was obtained through BEI Resources, MR4, NIAID, NIH) or Calf Thymus DNA (Sigma) at 10 μg/ml in PBS 1X, and allowed to evaporate (PS) at RT for \>16 hr of incubation at 4°C. Plates were washed five times with PBS 0.05% Tween 20 and then blocked for 1 hr with PBS 3% BSA. Plasma from patients was diluted at 1:100 in blocking buffer and incubated for 2 hr at 37°C. Plates were washed again five times and incubated with anti-human IgG-HRP (GE Healthcare) for 1 hr at 37°C. Plates were washed five more times and TMB substrate (BD Biosciences) was added until the desired color was obtained. The reaction was stopped by with Stop buffer (Biolegend) and absorbance was read at 450 nm. The mean OD at 450 nm from triplicate wells was compared with the same dilution of a reference positive serum to calculate relative units (RU). For human PBMC ELISAs, a similar process was performed but using human erythrocyte lysates or PS for coating, undiluted PBMC culture supernantants and anti-human IgM-HRP (Millipore) for detection. Three technical replicates for each plasma sample (independent wells in the same plate) were performed for ELISA. The average value of technical replicates for each sample was used for linear regression analysis. Each ELISA was performed at least twice. Only one representative result is shown.

Erythrocyte lysis {#s4-6}
-----------------

Assessment of the erythrocyte lysis capacity of plasma was performed following previously described methods with small modifications ([@bib19]). First, fresh healthy donor erythrocytes were treated with ionomycin at 2.5 µM (Life Technologies) to stress erythrocytes and to induce exposure of PS ([@bib17]). Erythrocytes were then washed twice with PBS and incubated with heat-inactivated plasma from either patients or uninfected controls (8% of total volume) along with 3.5% of AB type healthy plasma (Sigma) as a complement source for 1.5--2 hr. For Annexin V blocking experiments, the same protocol was used but 0.5 µM Annexin V (Biolegend) or its buffer alone were preincubated with the RBCs for 30 min. Plates were then spun down with reduced break and supernatants were carefully collected. Supernatants were read in a spectrophotometer at 414 nm to assess erythrocyte lysis. Results are shown as percentage of maximal lysis (erythrocytes lysed by water).

ELISPOT assay {#s4-7}
-------------

ELISPOTs were performed as previously reported ([@bib37]). PBMC from a healthy US donor were obtained. Human PBMC were seeded in flat 96-wells at a density of 2.5 × 10^4^ per well. *P.-falciparum*-infected erythrocyte lysates were prepared as mentioned before and added at a ratio of 1:10 (PBMC:erythrocytes) and cultured in serum-free hematopoietic cell X- VIVO 15 medium (Lonza) for 6 days. Specific B-cell populations were enriched through magnetic bead sorting (Miltenyi) by positive selection with a combination of purified biotinylated anti-FcRL5 antibody (atypical)/anti biotin beads or anti-CD27 (plasma/classical memory cell) coated magnetic beads. Enrichment yield was assessed by flow cytometry prior to addition to plate.

For ELISPOT, 5 × 10^4^ cells were added per well and incubated in X- VIVO 15 medium (Lonza) in 96-well Costar 3590 ELISA plates (Corning Life Sciences, Tewksbury, MA) precoated with either capture anti-IgM (15 µg/ml), PS (100 µg/ml in ethanol) (Sigma, St. Louis, MO), PfEBA (15 µg/ml) or PBS 10% BSA as control for 20 hr at 37°C with 5% CO~2~. Following extensive washings, anti-human IgM biotinylated detection antibody (EMD Millipore) was added at 1 μg/ml diluted in PBS 0.5% FBS for 2 hr at RT. Streptavidin-horseradish peroxidase (Mabtech AB, Nacka Strand, Sweden) was added diluted in PBS 0.5% FBS for 1 hr at RT. Plates were developed with TMB substrate (Mabtech AB, Nacka Strand, Sweden) for 15--20 min and then washed extensively with water. Spots were quantified by microscopy. Spots in wells coated with PS or PfEBA are representative of antigen-responsive B-cells. Spots in wells coated with anti-IgM are representative of total antibody secreting cells (ASC).

Biological replicates (samples from three different healthy donors in three independent experiments) were used for the ELISPOT assay and the related FACs analysis. Three technical replicates (independent wells in the same plate) were performed for each experiment.

Statistical analysis {#s4-8}
--------------------

Data were analyzed using Prism (GraphPad Software). Unpaired t-tests were used to identify statistical differences between groups of samples. A p-value of \<0.05 was considered significant. Correlations were performed using non-parametric Spearman correlation analysis. Error bars represent the standard deviations (SD) of data from all of the patients or donors used in each experiment.
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**Acceptance summary:**

Rivera-Correa and colleagues probe an important question concerning malaria and anemia. On the basis of results recorded from the \"first-time\" malaria-infected adult subjects, the authors construct correlations that anti-phosphatidylserine autoantibodies, secreted by *Plasmodium falciparum*-induced atypical memory B cells, are involved in the lysis of uninfected red blood cells, thus leading to anemia. This work, touching on the etiology of malaria-associated anemia, represents an important aspect of malaria-associated pathology. These clinical observations increase our understanding of the processes that potentially lead to anemia and thus provide a framework for both researchers and clinicians to develop effective approaches for treating malaria-induced pathologies.

**Decision letter after peer review:**

Thank you for sending your article entitled \"Atypical memory B-cells are associated with *Plasmodium falciparum* anemia through anti-phosphatidylserine antibodies\" for peer review at *eLife*. Your article is being evaluated by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation is being overseen by Satyajit Rath as the Senior Editor.

Given the list of essential revisions, including new experiments, the editors and reviewers invite you to respond within the next two weeks with an action plan and timetable for the completion of the additional work. We plan to share your responses with the reviewers and then issue a binding recommendation.

There following are some of the major concerns expressed by the reviewers.

1\) Additional in vitro experiments need to performed to demonstrate:

a\) That indeed the T-bet^+^FcRL5^+^ B cells selectively do produce PS antibodies that correlate with anemia;

b\) That the anti-PS antibodies do engage in the lysis of RBC.

c\) That T-bet^+^ B cells correlate with anti-parasite antibody (responses against whole parasite lysates.

2\) Regarding the correlative data presented in the manuscript, the concern is that the results were reported with linear regression. Given the small number of patients, several significant correlations may have been driven by 1 or 2 outliers. Therefore, nonparametric assessments would have been more appropriate. In addition, some re-analyses should be provided to account for repeated measurements within individuals.

3\) To strengthen the authors\' claim -- if at all possible -- it would be to conduct these experiments with samples from another, e.g., endemic cohort.

Reviewer \#1:

In this manuscript Rivera-Correa and colleagues probe an important question concerning anti-PS-specific antibodies (autoimmune) produced by atypical B cells as a probable cause of anemia amongst persons suffering from malaria infection. On the basis of data obtained from a group of *Plasmodium falciparum*-infected subjects who returned from African countries, the authors constructed correlations about the increased frequency of atypical memory B cells expressing FcRL5 and producing anti phosphatidylserine (PS) antibodies that are ultimately involved in the lysis of uninfected red blood cells, hence anemia.

The authors have previously published similar work on malaria inducing anemia via the anti-PS antibodies in a mouse model and now they extend this investigation to human subjects, which is an important aspect of malaria-associated pathology and thus it adds significant value to the study. The authors also claim that their cohort with a \"possibly\" one time malaria infection enhances the importance of their correlative analyses as recurrent or chronic malaria infections amongst residents of endemic areas complicate the function of the atypical B cells, since for the most part these B cells are unresponsive.

Although the authors conducted their investigation with a seemingly adequate number of subjects, several key aspects of the study group such as malaria infection vis-à-vis sampling of PBMC are not well presented. Such omission makes it rather difficult to understand and properly interpret the results. For example, what level of certainty can the authors provide that this was only \"one time malaria infection\" and that the subjects did not suffer from malaria previously? In Table 1, the data show the days since treatment. Is it also the time when the PBMCs were sampled? If not, when and how many times were the PBMC drawn and sera obtained? According to the data provided in the Table, there is a rather high variation as to the time since the subjects received treatment. It is imperative to provide this explanation somewhere in the text, as the days vary considerably. i.e., day 1 -- 31. Is it possible that because of these variations, the results presented in Figure 1A, could be interpreted as showing two separate groups? Although, one does expect a certain level of variation in the level of any lymphocyte subsets in human populations, do the results showing T-bet^+^ B cells levels in *P. falciparum* infected persons reflect this expected variation, or do they reflect the time of treatment, the level of parasitemia, etc? These issues do need to be addressed to properly interpret the results. Also, it is not clear what the percentages in Figure 2B indicate. Are these percentages of T-bet^+^ B cells based on the number of CD19^+^B cells? Please clarify.

The key observation in this study is that the atypical FcRL5^+^B cells correlate with the production of anti-PS IgG antibodies, which in turn correlates with anemia. I would presume that the sera from which these antibodies were derived are still available. Additional (in vitro) experiments should be considered to demonstrate that the anti-PS IgG containing sera or isolated anti-PS antibodies derived from the Pf infected subjects lyse red blood cells. Results from these experiments would solidly confirm the correlative data presented by the authors.

As concerns experiments shown in Figure 6B, it is not entirely clear how the experiments were done and how the percentage of ELISPOTs were calculated? Please explain and explain abbreviation for ASC.

Reviewer \#2:

Summary: This is a well written manuscript that provides novel insights about malaria-induced anemia. In summary, the authors show that anemia (low hemoglobin) in patients with malaria is correlated with anti-PS antibodies and frequencies of FCRL5^+^ and T-bet B cells. Anemia does not correlate with parasitemia or levels of anti-parasite antibodies (anti-EBA), and is inversely correlated with classical MBC frequency. T-bet^+^ B cells expand in patients with malaria, then contract after drug treatment. FCRL5^+^ B cells from healthy donor PBMCs, when incubated with Pf erythrocyte lysate, will secrete anti-PS antibodies (to a significantly greater extent than CD27^+^ cells); both populations secrete roughly equal levels of anti-Pf antibodies.

Major points

1\) The key contribution of this manuscript is providing a potential autoimmune mechanism for malaria-associated anemia, as well as a potential function of T-bet^+^ atypical MBCs (but see objections to their interpretations on this below).

2\) There needs to be a better effort to incorporate recent developments in our understanding of what atypical / T-bet^+^ cells are. If atypical/T-bet^+^ cells are recently activated, optimally derived cells, then it follows that they are the main cells contributing to the circulating antibody pool for a recent infection (presumably after having to differentiate into antibody-secreting cells, which the study doesn\'t really mention). It makes sense that they\'re not going to have a lot of anti-DNA antibody because presumably this hasn\'t been elicited recently (at least is not the dominant recent stimulus).

What\'s more interesting about their data is that the T-bet^+^ cells correlate with anti-PS, but not anti-EBA (a parasite antigen). It would be nice to know if this correlation holds for anti-parasite antibodies in general (e.g., ELISA against whole parasite lysate). We know from published work in both human and mouse that atypical MBCs include cells with anti-Pf specificity (Muellenbeck et al., Krishnamurthy et al., Perez-Mazliah et al., Kim et al) and they also are enriched for anti-HIV antibodies in chronic HIV patients. So it doesn\'t seem to be universally true that T-bet^+^ atypicals are autoreactive B cells. But it may be the case that during malaria, the active Ab response is skewed toward PS rather than parasite antigens, and if so this could be a potentially very interesting immune evasion mechanism.

3\) It\'s hard to know what to take home from Figure 6 (in vitro stim of healthy donor PBMCs with infected RBC lysate). First of all, FCRL5 and CD27 aren\'t mutually exclusive markers for atMBCs and cMBCs; a decent fraction (5-45%) of CD27^+^ cells also express FCRL5 (Sullivan 2015, Kim 2019). So it\'s not clear what populations are being sorted in this expt-there is probably some overlap between the two. Also, since FCRL5 appears to be upregulated transiently on activated B cells (e.g. Dement-Brown et al. 2012), it\'s possible that this population just includes most or all of the activated B cells (which would be consistent with the greater \# of ASCs observed in the FCRL5^+^ compared to CD27^+^ wells).

4\) Because of the authors\' focus on the nature of the T-bet^+^ FCRL5^+^ cells as producers of autoreactive (anti-PS) antibodies but not anti-parasite antibodies, a key question is whether the FCRL5^+^ subset selectively produces anti-PS. No stats are included in Figure 6B to compare the number of FCRL5^+^ ASCs producing anti-PS versus anti-PfEBA (gray bars)- are these numbers significantly different? It might be informative to try stimulating PBMCs with another, unrelated antigen (or even look at additional self and Pf antigens with the same stimulus) and see if this pattern holds true (i.e. that most ASCs are found in the FCRL5^+^ pool). This would be consistent with recent literature demonstrating that FCRL5^+^ B cells are responsive, recently activated cells (Perez-Mazliah et al., Kim et al.) but would weaken the authors\' interpretation of this subset as a uniquely autoreactive subset.

5\) The authors don\'t find a correlation between anti-EBA antibodies and any B cell subsets assessed (Figure 5, subsection "Anti-parasite antibodies do not correlate with FcRL5^+^ T-bet^+^ atypical B-cells during malarial anemia in *P. falciparum*-infected patients"). But we know that some anti-parasite antibodies are made. So... where are those antibodies coming from? Is EBA a good representative Ag? Are multiple B cell subsets contributing those Ab levels? Is it all coming from plasma cells in bone marrow and cannot be measured from PBMCs? If so, then is the fact that most B cell subsets (including plasma cells) don\'t correlate with anti-PS antibodies meaningful? Maybe the antibodies come from plasma cells in BM, and in fact T-bet^+^ B cells are an indirect marker of recency since infection, or immune status; and these things might also correlate with anemia severity.

Reviewer \#3:

In this paper by Rivera-Correa and colleagues, the authors report an intriguing association between anti-phosphotidyl serine antibodies, FcRL5^+^T-bet^+^B cells, and hemoglobin levels among patients presenting with symptomatic malaria. The authors further describe in vitro experiments detailing that FCRL5^+^ T-bet^+^ B cells expand after coculture of naïve PBMC with Pf lysate, and that these expanded cells appear to produce anti-PS antibodies, which strengthens the observations reported and suggest that malarial anemia may be mediated in part by auto-immune antibody production by this B cell subset. The manuscript is clearly written and easy to follow. My major concern with the data presented in this manuscript is that the main results (Figures 1-5) are mainly correlations, and that the correlation results were reported with linear regression. With the small patient numbers (n=19) several of the \"significant\" correlations may have been driven by 1 or 2 \"outliers\" with lower hemoglobin, for example. Given the small numbers, nonparametric assessments would have been more appropriate (i.e. Spearman\'s correlation coefficients as opposed to linear regression). Importantly, in many of the figures, there appears to be 27 data points, but in the Materials and methods, the authors state that there were 19 patients (7 with convalescent samples). Thus, one would surmise that the figures reflect 1 data point from 12 individuals, and two data points from 7 individuals. Assuming that these repeated measurements are correlated, the authors should have performed some analysis to account for repeated measures within individuals (e.g. generalized estimating equations or mixed effects linear regression) since autocorrelation could also be driving these associations.

One possible way to strengthen the authors\' claims would be to obtain and analyze samples from a secondary cohort (e.g., an endemic cohort, if obtaining samples from a traveler\'s clinic is too time consuming.) The authors defend the choice of using a traveler\'s cohort in the discussion, since in many instances this might represent a primary infection, although I think it would also be very interesting to see if frequencies of FCRL5^+^T-bet^+^ B cells correlate with anti-PS antibodies in endemic settings as well.

Materials and methods: 19 patients and 4 controls

Results section -- 27 samples? This is misleading. Would state X patients, 27 unique samples. (but isn\'t it actually 20 patients? Your numbering is from 100-119, so you would also count patient 0?)

Concern in Figure 1A: 2 patients with Hb \<5 but not in table? What are these 2 measurements? Assuming this reflects Hb measured in all patients at the time that parasitemia was assessed (?Day 0) This data should be included in Table 1.

Table 1 generally is difficult to follow and should be clarified (potentially in legend or with updated column headers)

-- Days since treatment start -- needs clarification that this is the day of PBMC/plasma/Hb sampling.

-- Also -- for 7 individuals, the 2nd visit is also detailed in the table. I would argue that this information should be on the same \"row\" in columns to the right rather than a separate row.

-- Hb measurement is at the date of sampling -- do you also have hemoglobin at date parasitemia measured? (as above)

-- Why does parasite count in Table 1 oscillate between% and parasites/μl? Not easy to interpret this in the table. Presumably these were all converted to parasites/µl for use in Figure 1A. Would use one standard metric here.

Results section the authors state that hemoglobin does not correlate with parasitemia, but this is an incorrect statement -- they are not \"significantly\" correlated, although, visually, a positive correlation is suggested.

Results section: -- \"expression of T-bet in CD27^-^CD21^-^FcRL5^+^ B-cells is directly correlated\". Assuming that you assessed co-expression of T-bet in FCRL5^+^ cells? Would be a more direct analysis vs. showing the correlation.

Discussion

Paragraph one: you didn\'t actually test the hypothesis that malaria-associated anemia is mediated by an autoimmune anti-PS response -- you tested the correlation per se, which would be consistent with a causal relationship. Would be a little more judicious in your discussion/conclusions.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Atypical memory B-cells are associated with *Plasmodium falciparum* anemia through anti-phosphatidylserine antibodies\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Satyajit Rath (Senior Editor) and two reviewers, one of whom is a member of our Board of Reviewing Editors.

In the revised version of the manuscript, Juan Rivera-Correa and colleagues describe an interesting observations concerning the cause of anemia that accompanies malaria in *Plasmodium falciparum* exposed persons. It appears that *Plasmodium falciparum* infected red blood cells activate B cells that express phenotypic markers indicative of atypical B cell population (FcRL5^+^T-bet^+^) and such induced B cells produce antibodies that are autoreactive against phosphatidylserine that cause lysis of uninfected red blood cells. The authors found that the population of these atypical B cells did increase in European travels, who suffered from malaria episode(s) while visiting African countries. The authors demonstrate that atypical FcRL5^+^T-bet^+^ B cells are greatly expanded in acute malaria in *P. falciparum*-infected patients and correlate with both anemia and plasma anti-PS antibody levels in these patients. The authors have also confirmed these observations in vitro conducted experiments. These are novel observations showing that human atypical B cells produce anti-PS autoantibodies that play a significant role in the pathogenesis of human malaria anemia.

The manuscript has been improved but a few remaining issues, mainly editorial in nature, need to be addressed before acceptance. The issues to consider for revision are outlined below:

1\) The introduction to each section fails to capture and integrate narratively the flow of the results. Please make a few editorial edits to better highlight this flow and integration. For example, the first sentence of the second section of the Results reads \"Our first aim was..\". However, the first section of the Results section seems to be the first aim, which is to establish that autoantibodies correlate with anemia and erythrocyte lysis in malaria patients. Similarly, the first sentence of the third section reads, \"Our main goal\".. Please reword to simply state, \"We next sought to determine whether B cell subsets described above correlate with hemoglobin levels.

2\) Gating plots and analysis of Figure 3 and Figure 4. AS written, it seems as though the analysis reported in section 2 (Figure 3) and section 3 (Figure 4) use different gating strategies to define populations of atypical memory B cells. Hopefully this is not the case. For example, in section 2, it states that AtMBC were defined as CD19^+^, FCRL5^+^, T-bet^+^. However, in Section 3, it states that AtMBC were defined as CD19^+^CD21^-^CD27^-^FCRL5^+^T-bet^+^. Please 1) integrate the two \"definitions\" into one and present these in section 2 of the results, with one integrated gating plot included (not separated into one in Figure 3 and one in Figure 4 ---figure supplement.

Relatedly- gating figure (Figure 4---figure supplement). Not a very convincing plot of atypical memory B cells as cd27^-^cd21^-^ cells (2.9%?). Do you have a more representative gating figure that can be included instead? (especially if your median in tourists is close to 9%., and given the beautiful plot shown in Figure 3?).

3\) Results subsection "Anti-parasite antibodies do not correlate with FcRL5^+^ T-bet^+^ atypical memory B-cells in *P. falciparum*-infected patients" header. Response to only one parasite antigen was measured, so this section header should be changed to something similar to the Figure 6 figure legend.

One suggestion:

\"Atypical memory B-cell frequencies do not significantly correlate with anti-PfEBA antibodies in *P. falciparum* infected patients\".

4\) In Discussion, paragraph seven, there are a duplication in text the correct text needs to be included.

10.7554/eLife.48309.045

Author response

> There following are some of the major concerns expressed by the reviewers.
>
> 1\) Additional in vitro experiments need to performed to demonstrate:
>
> a\) That indeed the T-bet^+^FcRL5^+^ B cells selectively do produce PS antibodies that correlate with anemia;
>
> b\) That the anti-PS antibodies do engage in the lysis of RBC.
>
> c\) That T-bet^+^ B cells correlate with anti-parasite antibody (responses against whole parasite lysates.
>
> 2\) Regarding the correlative data presented in the manuscript, the concern is that the results were reported with linear regression. Given the small number of patients, several significant correlations may have been driven by 1 or 2 outliers. Therefore, nonparametric assessments would have been more appropriate. In addition, some re-analyses should be provided to account for repeated measurements within individuals.
>
> 3\) To strengthen the authors\' claim -- if at all possible -- it would be to conduct these experiments with samples from a another, e.g., endemic cohort.
>
> Reviewer \#1:
>
> In this manuscript Rivera-Correa and colleagues probe an important question concerning anti-PS-specific antibodies (autoimmune) produced by atypical B cells as a probable cause of anemia amongst persons suffering from malaria infection. On the basis of data obtained from a group of Plasmodium falciparum-infected subjects who returned from African countries, the authors constructed correlations about the increased frequency of atypical memory B cells expressing FcRL5 and producing anti phosphatidylserine (PS) antibodies that are ultimately involved in the lysis of uninfected red blood cells, hence anemia.
>
> The authors have previously published similar work on malaria inducing anemia via the anti-PS antibodies in a mouse model and now they extend this investigation to human subjects, which is an important aspect of malaria-associated pathology and thus it adds significant value to the study. The authors also claim that their cohort with a \"possibly\" one time malaria infection enhances the importance of their correlative analyses as recurrent or chronic malaria infections amongst residents of endemic areas complicate the function of the atypical B cells, since for the most part these B cells are unresponsive.
>
> Although the authors conducted their investigation with a seemingly adequate number of subjects, several key aspects of the study group such as malaria infection vis-à-vis sampling of PBMC are not well presented. Such omission makes it rather difficult to understand and properly interpret the results. For example, what level of certainty can the authors provide that this was only \"one time malaria infection\" and that the subjects did not suffer from malaria previously?

We thank the reviewer for the insightful comments and detailed review. We have analyzed the patient's data on previous malaria episodes finding that all patients in the Tourist group reported never suffering from malaria before, which is likely to be accurate since they were all born in Germany. On the other hand, all patients in the VFR group reported having at least one previous episode of malaria. The time from the last malaria episode was not reported. This information is now included in Results section.

> In Table 1, the data show the days since treatment. Is it also the time when the PBMCs were sampled? If not, when and how many times were the PBMC drawn and sera obtained?

Table 1 has been modified to clarify that it shows the "Days since treatment start to sampling". Each line represents a collected sample, when more than one sample was collected from the same patient two lines with the same patient ID are shown in the table.

> According to the data provided in the Table, there is a rather high variation as to the time since the subjects received treatment. It is imperative to provide this explanation somewhere in the text, as the days vary considerably. i.e., day 1 -- 31. Is it possible that because of these variations, the results presented in Figure 1A, could be interpreted as showing two separate groups? Although, one does expect a certain level of variation in the level of any lymphocyte subsets in human populations, do the results showing T-bet^+^B cells levels in P. falciparum infected persons reflect this expected variation, or do they reflect the time of treatment, the level of parasitemia, etc? These issues do need to be addressed to properly interpret the results.

To address this concern, we have performed the analysis of 'days after treatment' and hemoglobin, which showed no significant correlation, indicating that the variations on hemoglobin levels are not just a consequence of time after parasite clearance.

We also observed a significant direct correlation between the levels of atypical MBCs and the days after treatment, which suggests that the levels of aMBCs keep increasing after treatment. This increase in the levels of aMBCs with time after treatment is compatible with aMBCs being activated during infection and continuing proliferation after parasite clearance.

This is now included in Results section and in (Figure 2---figure supplement 3).

We have also clarified that all patients were treated at the day of presentation which is considered day 0 (now included in Materials and methods section).

> Also, it is not clear what the percentages in Figure 2B indicate. Are these percentages of T-bet^+^B cells based on the number of CD19^+^B cells? Please clarify.

The percentages of T-bet^+^ B cells are based on the gating of CD19^+^ cells as indicated in Figure 2A. This is clarified in Figure legend 2.

> The key observation in this study is that the atypical FcRL5^+^B cells correlate with the production of anti-PS IgG antibodies, which in turn correlates with anemia. I would presume that the sera from which these antibodies were derived are still available. Additional (in vitro) experiments should be considered to demonstrate that the anti-PS IgG containing sera or isolated anti-PS antibodies derived from the Pf infected subjects lyse red blood cells. Results from these experiments would solidly confirm the correlative data presented by the authors.

As suggested by the reviewer, we have tested the capacity of the patient's plasma to lyse erythrocytes finding increased erythrocyte lysis by patient's plasma compared to healthy controls and a direct correlation of levels of anti-PS antibodies and erythrocyte lysis capacity of plasma. The erythrocyte lysis capacity is partially inhibited by annexin V, which specifically binds to PS, and inhibits the binding of anti-PS antibodies. This experiment was performed with the samples from 6 patients and 3 healthy controls from which there was enough volume remaining. We have also observed that levels of anti-PS antibodies correlate with the levels of LDH in patients. This is now included in Results section and in new Figure 2 and commented in the Discussion.

> As concerns experiments shown in Figure 6B, it is not entirely clear how the experiments were done and how the percentage of ELISPOTs were calculated? Please explain and explain abbreviation for ASC.

Materials and methods section includes now a detailed explanation on how the percentages were calculated in the ELISPOTs and the explanation for ASC (antibody-secreting cells).

> Reviewer \#2:
>
> Summary: This is a well written manuscript that provides novel insights about malaria-induced anemia. In summary, the authors show that anemia (low hemoglobin) in patients with malaria is correlated with anti-PS antibodies and frequencies of FCRL5^+^ and T-bet B cells. Anemia does not correlate with parasitemia or levels of anti-parasite antibodies (anti-EBA), and is inversely correlated with classical MBC frequency. T-bet^+^ B cells expand in patients with malaria, then contract after drug treatment. FCRL5^+^ B cells from healthy donor PBMCs, when incubated with Pf erythrocyte lysate, will secrete anti-PS antibodies (to a significantly greater extent than CD27^+^ cells); both populations secrete roughly equal levels of anti-Pf antibodies.
>
> Major points
>
> 1\) The key contribution of this manuscript is providing a potential autoimmune mechanism for malaria-associated anemia, as well as a potential function of Tbet+ atypical MBCs (but see objections to their interpretations on this below).
>
> 2\) There needs to be a better effort to incorporate recent developments in our understanding of what atypical / T-bet^+^ cells are. If atypical/T-bet^+^ cells are recently activated, optimally derived cells, then it follows that they are the main cells contributing to the circulating antibody pool for a recent infection (presumably after having to differentiate into antibody-secreting cells, which the study doesn\'t really mention). It makes sense that they\'re not going to have a lot of anti-DNA antibody because presumably this hasn\'t been elicited recently (at least is not the dominant recent stimulus).

We thank the reviewer for all insightful comments that have improved significantly the quality of the manuscript.

The recent literature in atypical / T-bet^+^ B-cells has provided insights of the heterogenic population that the T-bet marker alone can indicate. Double expression of T-bet and FcRL5 was used in our study to better define the population of atypical memory B-cells, as has been described in malaria patients (Sullivan et al. 2015). This point has been explained in the Discussion.

> What\'s more interesting about their data is that the T-bet^+^ cells correlate with anti-PS, but not anti-EBA (a parasite antigen). It would be nice to know if this correlation holds for anti-parasite antibodies in general (e.g., ELISA against whole parasite lysate).

We agree with the reviewer that it would be interesting to see the correlation with whole anti-parasite antibodies, but we would predict that testing for this correlation with whole parasite lysates (either using lysates of infected RBCs or lysates of purified merozoites), will not be conclusive since the parasite (and infected RBC) lysates contain large amounts of PS.

> We know from published work in both human and mouse that atypical MBCs include cells with anti-Pf specificity (Muellenbeck et al., Krishnamurthy et al., Perez-Mazliah et al., Kim et al) and they also are enriched for anti-HIV antibodies in chronic HIV patients. So it doesn\'t seem to be universally true that T-bet^+^ atypicals are autoreactive B cells. But it may be the case that during malaria, the active Ab response is skewed toward PS rather than parasite antigens, and if so this could be a potentially very interesting immune evasion mechanism.

We have included a sentence and the references in the Discussion section to clarify that atypical MBCs include cells with specificity against *P. falciparum* antigens, as previously described. This is in agreement with our results in Figure 6, where a population of FcRL5-enriched cells shows reactivity against PfEBA antigen.

> 3\) It\'s hard to know what to take home from Figure 6 (in vitro stim of healthy donor PBMCs with infected RBC lysate). First of all, FCRL5 and CD27 aren\'t mutually exclusive markers for atMBCs and cMBCs; a decent fraction (5-45%) of CD27^+^ cells also express FCRL5 (Sullivan 2015, Kim 2019). So it\'s not clear what populations are being sorted in this expt-there is probably some overlap between the two. Also, since FCRL5 appears to be upregulated transiently on activated B cells (e.g. Dement-Brown et al. 2012), it\'s possible that this population just includes most or all of the activated B cells (which would be consistent with the greater \# of ASCs observed in the FCRL5^+^ compared to CD27^+^ wells).

The main purpose of Figure 6 is to link directly atypical FcRL5^+^ B cells with the secretion of autoimmune anti-PS antibodies. For this purpose, we compared FcRL5^+^ cells and CD27^+^ cells, which will differentially include plasmablasts/plasma cells as well as classical Memory B-cells. As the reviewer points out, these markers are not mutually exclusive and both enriched populations will include recently activated cells. In fact, CD27^+^ enriched cells had higher numbers of total antibody secreting cells (ASCs) than FcRL5^+^ when analyzed by total IgM spots (now included as Figure 7---figure supplement 1), which indicates that activated ASCs are found in both populations (CD27^+^ and FcRL5^+^) and that FcRL5^+^ population does not include most or all of the activated B cells.

Distinctly, quantification of PS-specific ASCs show that these cells are more frequent among FcRL5^+^ cells compared to CD27^+^ cells, despite having similar number of PfEBA-specific ASCs. These results indicate that even if CD27^+^ cells have a higher proportion of ASCs in general, FcRL5^+^ cells contain more anti-PS secreting cells. A sentence explaining these results is now included in Results section.

> 4\) Because of the authors\' focus on the nature of the T-bet^+^ FCRL5^+^ cells as producers of autoreactive (anti-PS) antibodies but not anti-parasite antibodies, a key question is whether the FCRL5^+^ subset selectively produces anti-PS. No stats are included in Figure 6B to compare the number of FCRL5^+^ ASCs producing anti-PS versus anti-PfEBA (gray bars)- are these numbers significantly different?

No significant difference is observed between the number of FCRL5^+^ ASCs producing anti-PS versus anti-PfEBA (now included in the graph). This suggests that the FcLR5 subset can efficiently produce both autoimmune and anti-parasite antibodies. This is now explained in the Results section.

> It might be informative to try stimulating PBMCs with another, unrelated antigen (or even look at additional self and Pf antigens with the same stimulus) and see if this pattern holds true (i.e. that most ASCs are found in the FCRL5^+^ pool). This would be consistent with recent literature demonstrating that FCRL5^+^ B cells are responsive, recently activated cells (Perez-Mazliah et al., Kim et al.) but would weaken the authors\' interpretation of this subset as a uniquely autoreactive subset.

As requested by the reviewer, we have attempted the stimulation of PBMC with a specific *P. falciparum* antigen, HRPII, and with uninfected erythrocyte lysate. We did not observe a significant expansion of T-bet^+^ FCRL5^+^ cells in these cultures (now included as Figure 7---figure supplement 2). This may be explained by the observation that three different signals are needed for optimal expansion of these cells in vitro: B-cell stimulation, specific inflammatory cytokines (IFNγ) and Plasmodium DNA (Rivera-Correa et al. 2017 Nat. Comm.) These three stimuli are present when PBMCs are incubated with whole *P. falciparum*-infected erythrocyte lysates, hence providing all the signals needed for expansion of T-bet^+^ FCRL5^+^ and production of anti-PS antibodies. However, no parasite DNA is present when the stimulus is a purified protein or uninfected erythrocyte lysates. This is now explained in the Results section.

> 5\) The authors don\'t find a correlation between anti-EBA antibodies and any B cell subsets assessed (Figure 5, subsection "Anti-parasite antibodies do not correlate with FCRL5^+^ T-bet^+^ atypical B-cells during malarial anemia in P. falciparum-infected patients"). But we know that some anti-parasite antibodies are made. So... where are those antibodies coming from? Is EBA a good representative Ag? Are multiple B cell subsets contributing those Ab levels?

As the reviewer indicates, anti-Plasmodium antibodies are produced by at least two different subsets of B cells: atypical and classical (Muellenbeck et al., 2013), which may explain the lack of significant correlation with any of them in our study, which has a limited number of samples, and therefore is only able to detect strong correlations.

The differential correlation of anti-PS antibodies with atypical B cells versus other B cell subsets should be interpreted as these other subsets may contribute to a lesser extent (or do not contribute at all) to the production of anti-PS antibodies when compared to atypical B cells. We have worded the conclusions carefully to avoid over-interpretation of the results.

> Is it all coming from plasma cells in bone marrow and cannot be measured from PBMCs? If so, then is the fact that most B cell subsets (including plasma cells) don\'t correlate with anti-PS antibodies meaningful? Maybe the antibodies come from plasma cells in BM, and in fact T-bet^+^ B cells are an indirect marker of recency since infection, or immune status; and these things might also correlate with anemia severity.

We would like to point out that, although atypical MBCs increase with time after treatment, suggesting that they could be a marker of recency, hemoglobin levels do not correlate with time after treatment (Figure 3---figure supplement 3), indicating that the time at which samples were collected is not the cause of the correlation between atypical MBC and hemoglobin levels.

Previous studies have established that malaria patients present antibody-secreting classical and atypical MBCs in the circulation (Muellenbeck et al., 2013), indicating that at least a fraction of the total antibodies are not produced by plasma cells in the bone marrow. Bone-marrow plasma cells are normally long-lived and produce low levels of high affinity antibodies against foreign antigens, but they are not considered producers of autoimmune antibodies in healthy adults (Lightman et al. 2019). Additionally, data from Plasmodium infections in mice (Fernandez-Arias et al., 2016 and Rivera-Correa et al. 2017) shows that anti-PS antibody levels decrease rapidly after infection, which would be unusual for bone marrow resident plasma cells.

> Reviewer \#3:
>
> In this paper by Rivera-Correa and colleagues, the authors report an intriguing association between anti-phosphotidyl serine antibodies, FcRL5^+^ T-bet^+^B cells, and hemoglobin levels among patients presenting with symptomatic malaria. The authors further describe in vitro experiments detailing that FCRL5^+^ T-bet^+^ B cells expand after coculture of naïve PBMC with Pf lysate, and that these expanded cells appear to produce anti-PS antibodies, which strengthens the observations reported and suggest that malarial anemia may be mediated in part by auto-immune antibody production by this B cell subset. The manuscript is clearly written and easy to follow. My major concern with the data presented in this manuscript is that the main results (Figures 1-5) are mainly correlations, and that the correlation results were reported with linear regression. With the small patient numbers (n=19) several of the \"significant\" correlations may have been driven by 1 or 2 \"outliers\" with lower hemoglobin, for example. Given the small numbers, nonparametric assessments would have been more appropriate (i.e. Spearman\'s correlation coefficients as opposed to linear regression).

We thank the reviewer for the insightful comments and detailed review. We believe that the quality of the manuscript has been greatly improved.

As suggested by the reviewer, we have now analyzed the data using nonparametric assessment methods (Spearman's correlation) in all correlations. All figures have been updated to show the results of the new analysis.

> Importantly, in many of the figures, there appears to be 27 data points, but in the Materials and methods, the authors state that there were 19 patients (7 with convalescent samples). Thus, one would surmise that the figures reflect 1 data point from 12 individuals, and two data points from 7 individuals. Assuming that these repeated measurements are correlated, the authors should have performed some analysis to account for repeated measures within individuals (e.g. generalized estimating equations or mixed effects linear regression) since autocorrelation could also be driving these associations.

We have modified the text to clarify that the analysis was performed with 31 unique samples from 24 patients (Results section). We have performed an analysis of the repeated samples by Spearman's correlation method, finding that there is no correlation in atypical MBCs between repeated measurements. This is now mentioned in Materials and methods section.

> One possible way to strengthen the authors\' claims would be to obtain and analyze samples from a secondary cohort (e.g., an endemic cohort, if obtaining samples from a traveler\'s clinic is too time consuming.) The authors defend the choice of using a traveler\'s cohort in the discussion, since in many instances this might represent a primary infection, although I think it would also be very interesting to see if frequencies of FCRL5^+^ T-bet^+^ B cells correlate with anti-PS antibodies in endemic settings as well.

We agree that this comparison would be very interesting, however, we do not have access to the large number of PBMC that are required for this type of analysis from other cohorts in endemic areas since primarily children are affected, and only small volumes of blood can be drawn.

> Materials and methods: 19 patients and 4 controls
>
> Results section -- 27 samples? This is misleading. Would state X patients, 27 unique samples. (but isn\'t it actually 20 patients? Your numbering is from 100-119, so you would also count patient 0?)

This has been corrected in the Results section. It is 24 patients (thank you for noticing this error) and a total of 31 samples.

> Concern in Figure 1A: 2 patients with Hb \<5 but not in table? What are these 2 measurements? Assuming this reflects Hb measured in all patients at the time that parasitemia was assessed (?Day 0) This data should be included in Table 1.

There were no patients with Hb\<5. This was a typing error in this particular graph. No other graph included these.

> Table 1 generally is difficult to follow and should be clarified (potentially in legend or with updated column headers)
>
> -- Days since treatment start -- needs clarification that this is the day of PBMC/plasma/Hb sampling.
>
> -- Also for 7 individuals, the 2nd visit is also detailed in the table. I would argue that this information should be on the same \"row\" in columns to the right rather than a separate row.
>
> -- Hb measurement is at the date of sampling -- do you also have hemoglobin at date parasitemia measured? (as above)
>
> -- Why does parasite count in Table 1 oscillate between% and parasites/ul? Not easy to interpret this in the table. Presumably these were all converted to parasites/µl for use in Figure 1A. Would use one standard metric here.

Table 1 has been modified to clarify that it shows the "Days since treatment start to sampling". Each line represents a collected sample, when more than one sample was collected from the same patient two lines with the same patient ID are shown in the table (data cannot be compressed into one single line, since there are two values for several parameters). Hemoglobin levels at day of presentation are now included. Parasitemias are all now expressed as parasites/µl.

> Results section the authors state that hemoglobin does not correlate with parasitemia, but this is an incorrect statement -- they are not \"significantly\" correlated, although, visually, a positive correlation is suggested.

This is now corrected in the new version of the manuscript

> Results section: \"expression of T-bet in CD27^-^CD21^-^FcRL5^+^ B-cells is directly correlated\". Assuming that you assessed co-expression of T-bet in FCRL5^+^ cells? Would be a more direct analysis vs. showing the correlation.

As suggested by the reviewer, we have used the double expression of T-bet and FcRL5 to define atypical MBCs (Figure 3A). We have used these markers to define atypical MBCs throughout the manuscript.

We have also analyzed the differential expression of T-bet in classical MBCs and FcRL5^+^ cells, finding that even if there is some expression of T-bet in classical MBCs, the expression of this marker is significantly higher in FcRL5^+^ cells. This is now included in Results and Figure 4---figure supplement 2.

> Discussion
>
> Paragraph one: you didn\'t actually test the hypothesis that malaria-associated anemia is mediated by an autoimmune anti-PS response -- you tested the correlation per se, which would be consistent with a causal relationship. Would be a little more judicious in your discussion/conclusions.

Corrected in the new version of the manuscript.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but a few remaining issues, mainly editorial in nature, need to be addressed before acceptance. The issues to consider for revision are outlined below:
>
> 1\) The introduction to each section fails to capture and integrate narratively the flow of the results. Please make a few editorial edits to better highlight this flow and integration. For example, the first sentence of the second section of the Results reads \"Our first aim was..\". However, the first section of the Results section seems to be the first aim, which is to establish that autoantibodies correlate with anemia and erythrocyte lysis in malaria patients. Similarly, the first sentence of the third section reads, \"Our main goal\".. Please reword to simply state, \"We next sought to determine whether B cell subsets described above correlate with hemoglobin levels.

These have been corrected in the new version of the manuscript.

> 2\) Gating plots and analysis of Figure 3 and Figure 4. AS written, it seems as though the analysis reported in section 2 (Figure 3) and section 3 (Figure 4) use different gating strategies to define populations of atypical memory B cells. Hopefully this is not the case. For example, in section 2, it states that AtMBC were defined as CD19^+^, FCRL5^+^, T-bet^+^. However, in Section 3, it states that AtMBC were defined as CD19^+^CD21^-^CD27^-^FCRL5^+^Tbet^+^. Please 1) integrate the two \"definitions\" into one and present these in section 2 of the results, with one integrated gating plot included (not separated into one in Figure 3 and one in Figure 4 ---figure supplement.
>
> Relatedly- gating figure (Figure 4---figure supplement). Not a very convincing plot of atypical memory B cells as cd27^-^cd21^-^ cells (2.9%?). Do you have a more representative gating figure that can be included instead? (especially if your median in tourists is close to 9%., and given the beautiful plot shown in Figure 3?).

Thanks for noticing this. AtMBC were defined as CD19^+^, FcRL5^+^, T-bet^+^ throughout the manuscript. In section 2, we have removed these (CD27^-^ CD21^-^) from the gating definition for atypical MBCs in subsection "Atypical memory FCRL5^+^ T-bet^+^ 180 B-cells correlate with hemoglobin levels in *P. falciparum*-infected returned travelers" and in Figure 4---figure supplement 1).

> 3\) Results subsection "Anti-parasite antibodies do not correlate with FcRL5^+^ T-bet^+^ atypical memory B-cells in P. falciparum-infected patients" header. Response to only one parasite antigen was measured, so this section header should be changed to something similar to the Figure 6 figure legend.
>
> One suggestion:
>
> \"Atypical memory B-cell frequencies do not significantly correlate with anti-PfEBA antibodies in P. falciparum infected patients\".

This has been modified following reviewer suggestion in the new version of the manuscript.

> 4\) In Discussion, paragraph seven, there are a duplication in text the correct text needs to be included.

The duplication has been deleted.
